Abstract
Patients with schizophrenia who were randomized to the novel glycine transporter inhibitor BI 425809 saw significant improvement in cognition compared with placebo in a 12‐week Phase 2 study. The most promising results were reported for daily doses of 10 and 25 mg. Study results were published in the March 2021 issue of Lancet Psychiatry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
